Actively Recruiting
Evaluating Tilrekimig With Medicated Creams in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis
Led by Pfizer · Updated on 2026-10-15
375
Participants Needed
21
Research Sites
12 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how well tilrekimig works and how safe it is when combined with medicated creams or ointments in adults and adolescents aged 12 years or older who have moderate to severe atopic dermatitis, also known as eczema. This common skin condition causes dry, itchy, red, and irritated skin. The study focuses on participants who have had atopic dermatitis for at least 12 months and have not responded well to standard topical treatments. Participants will be randomly assigned in a 21 ratio to receive either tilrekimig or a placebo through subcutaneous injections over a 20-week period. The study treatment period lasts 24 weeks, with the last dose given at week 20. After completing this phase, some participants may join a long-term extension study to continue monitoring the effects and safety of tilrekimig, while others will enter a 12-week safety follow-up ending 16 weeks after their last dose. During the study, participants will be monitored closely with evaluations including eczema severity assessments, quality of life questionnaires, and safety checks such as vital signs and laboratory tests. Researchers will measure outcomes like the proportion of participants showing improvement in eczema severity at week 16. The total participation time includes the treatment period and follow-up, lasting several months to assess both short-term and longer-term effects of the study medicine.
CONDITIONS
Brief Title
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here